SOHO 2023 | Treatment options for patients with early T-cell precursor ALL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses potential treatment options for patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) and highlights the importance of using genomic profiling to guide treatment decisions. Dr Jain also comments on new therapies being investigated in clinical trials, such as venetoclax, CAR-T therapy, and therapies already used to treat patients with acute myeloid leukemia (AML). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
